Association of X chromosome allelic losses with tumor malignancy has been identified in foregut but not in midgut endocrine neoplasms. The aim of this study was to investigate the association of deletions on X chromosome with malignancy in lung neuroendocrine tumors, another family of foregut neoplasms comprising four categories with increased malignancy: typical and atypical carcinoids, large cell neuroendocrine and small cell lung carcinomas. To evaluate loss of heterozygosity, DNA extracted from nine typical carcinoids, 17 atypical carcinoids, six large cell neuroendocrine carcinomas and five small cell lung carcinomas was PCRamplified for 18 microsatellite markers spanning the whole X chromosome. All tissue samples were formalinfixed and paraffin-embedded. X chromosome losses were absent in typical carcinoids, whereas they were found in nine out of 17 atypical carcinoids and in five out of six large cell neuroendocrine carcinomas (involving 28 and 70% of informative loci, respectively). On the contrary, deletions on X chromosome were an extremely rare event in small cell lung carcinomas. In atypical carcinoids, the presence of losses was associated with larger tumor size, higher pT status and advanced stage. No death occurred in atypical carcinoid patients without deletions on X chromosome, whereas all atypical carcinoid patients who had died from disease showed allelic losses. In conclusion, X chromosome allelic losses, absent in benign 'typical' carcinoids, progressively increased in frequency from intermediate-grade 'atypical' carcinoids to high-grade large cell neuroendocrine carcinomas. These results extend the association of deletions on X chromosome with malignancy, already demonstrated in other foregut endocrine neoplasms, to lung neuroendocrine tumors. The absence of X chromosome allelic losses in small cell lung carcinomas underlines a striking difference from large cell neuroendocrine carcinomas, possibly linked to different pathogenetic mechanisms of these two highly aggressive neuroendocrine lung tumors.
Neuroendocrine tumors of the lung represent a heterogeneous group of neoplasms sharing a common neuroendocrine phenotypic differentiation but differing from each other in their biological behavior and clinical aggressiveness. According to the WHO classification, 1 four distinct pathological entities are recognized: typical and atypical carcinoids, characterized by low and intermediate grades of malignancy, respectively; large cell neuroendocrine and small cell lung carcinomas, both of high-grade malignancy. Typical carcinoids are associated with an excellent prognosis and an overall 10-year survival rate of 90%, 2,3 even if 5-10% of cases may develop metastases to regional lymph nodes. 4 Atypical carcinoids are morphologically similar to typical carcinoids; however, they are larger in size, display a higher mitotic activity and show a less favorable prognosis, with a 10-year survival rate ranging from 25 to 60%. 2, 4 Large cell neuroendocrine carcinomas and small cell lung carcinomas are poorly differentiated neoplasms, both characterized by a poor prognosis, with a 10-year survival rate of 5 and 11%, respectively. 4 In their embryologic classification of carcinoid tumors, supported by histological and clinical features, Williams and Sandler 5 subdivided these neoplasms according to the embryonic divisions of the gut from which they derive. Accordingly, tumors of the bronchus, stomach and pancreas, which are all foregut derivatives, were separated from those of the midgut (small intestine, caecum and right to mid colon) and of the hindgut (descending colon and rectum). Previous studies from our laboratory showed a correlation between loss of heterozygosity (LOH) on X chromosome and malignancy in gastric and pancreatic endocrine tumors, of foregut derivation, but not in carcinoids of midgut and hindgut origin. 6, 7 The aim of the present study was to extend the analysis of the relationship between X chromosome LOH and malignancy to another group of foregutderived endocrine neoplasms, the lung neuroendocrine tumors. To this end, a fine allelotyping of X chromosome was performed on the four types of tumors encompassing the whole spectrum of neuroendocrine neoplasms of the lung. With the present detailed analysis of both chromosomal arms, we have attempted to provide more information on the X chromosome loci and related oncosuppressor genes potentially involved in the clinical behavior of foregut endocrine tumors.
Materials and methods

Tumors
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X chromosome in lung endocrine tumors T D'Adda et al and small cell components (#32b), both available for the study. Informed consent was obtained from all patients and/or guardians, according to Italian law. All tumors were examined independently by three pathologists expert in the field (MP, GP, CB) and classified according to the histopathological criteria proposed by the WHO classification 1 ( Figure  1 ), using the TNM staging system (TNM, 6th Edition, UICC, 2002). In cases of disagreement, the tumors were reviewed by all the experts together, until agreement was reached. According to WHO classification, typical carcinoids are characterized by a number of mitotic figures less than 2 per 10 high-power fields (HPFs), and by the absence of necrosis. Atypical carcinoids are identified by a number of mitotic figures ranging from 2 to 10 per 10 HPFs and/or by the presence of necrosis. Large cell neuroendocrine carcinomas and small cell lung carcinomas share a high mitotic rate (more than 10 mitotic figures per 10 HPFs) and the extensive necrosis, while they differ for the cytological characteristics of tumor cells, particularly cell size (nonsmall in large cell neuroendocrine carcinomas), nucleus/cytoplasmic ratio (low in large cell neuroendocrine carcinomas, high in small cell lung carcinomas), chromatin pattern (coarsely granular in large cell neuroendocrine carcinomas, finely and evenly dispersed in small cell lung carcinomas), and presence/absence of nucleoli (obvious in large cell neuroendocrine carcinomas, absent or inconspicuous in small cell lung carcinomas). In all the cases investigated, both tumoral and nontumoral tissue (ie, adjacent histologically normal lung parenchima and/or uninvolved regional lymph nodes from the same resected surgical specimens) were available. The study was performed on archival, routinely formalin-fixed and paraffin-embedded material. 
DNA Extraction
Serial 4-mm-thick histological sections stained with hematoxylin were examined under a stereomicroscope: normal and tumoral areas were manually microdissected using sterile scalpels. A neoplastic cellularity of at least 80% was obtained for each tumor sample. Microdissected tissues were suspended in an optimized buffer for tissue lysis, incubated overnight with Proteinase K, then DNA extraction and purification were performed using a commercial kit (Dneasy Tissue kit, QIAGEN Inc., Valencia, CA, USA), following the manufacturer's protocol. Quality and amplificability of DNA extracted from formalin-fixed, paraffin-embedded material were assessed by PCR for the human b-globin gene.
PCR Amplification
To evaluate the presence of LOH, 18 highly polymorphic microsatellite markers spanning the whole X chromosome (Table 2) were PCR amplified from tumor and control DNA using primers labeled with Beckman Coulter WellRED fluorescent dyes D2, D3, D4 (Beckman Coulter, Fullerton, CA, USA). All the microsatellite markers contained dinucleotide repeats. For PCR amplification, 2 ml of suitably diluted DNA were combined in a 25 ml reaction mixture containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 200 mM of each dNTP (Promega, Madison, WI, USA), 0.4 mM/L of each primer, 1.5-2.0 mM MgCl 2 and 1.25 U Taq polymerase (Promega, Madison, WI, USA). Data on annealing temperature and MgCl 2 concentration for each microsatellite marker investigated are listed in Table 2 . PCR amplifications consisted of 35 cycles and were performed in a Primus 25 (MWG-Biotech, Ebersberg, Germany) or in an AB 2700 (Applied Biosystems, Foster City, CA, USA) thermal cycler. The presence and correct size of PCR amplimers was checked by electrophoresis on a 2% agarose gel (Qbiogene Inc., Carlsbad, CA, USA).
Polyacrylamide Gel Electrophoresis and Fragment Analysis
To identify and precisely size the amplified DNA fragments, individual PCR products were run on a CEQ TM 2000XL capillary DNA sequencer (Beckman Coulter, Fullerton, CA, USA), with a linear polyacrylamide denaturing gel filling the capillary array (eight 33-cm-long silica capillaries) representing the separation medium. For each sample, 0.5-3 ml of PCR-amplified mixture and 0.3 ml of CEQ DNA size standard-400 (Beckman Coulter WellRED dye D1-coupled) were added to 25 ml of sample loading solution containing deionized formamide and loaded into a 96-well sample microplate. After automatic denaturation at 901C for 120 s, samples were run under the following electrophoretic conditions: capillary temperature 401C, injection voltage 2.0 kV for 30 s, separation voltage 7.5 kV for a run time of 35 min. Excitation of the WellRED dyes 
Evaluation of LOH
Heterozygosity, that is, the presence of two distinct alleles in normal tissue, is the essential requisite for evaluation of LOH. Peak height data produced by the CEQ2000XL Fragment Analysis software were used to calculate the following ratio:
ðlower allele=higher alleleÞ tum = ðlower allele=higher alleleÞ norm
Ratio values below 0.6, reflecting an allelic imbalance of 40% or more, were considered as indicators of allelic losses.
Evaluation of LOH at Each Microsatellite Marker
For each microsatellite marker investigated, the frequency of LOH was obtained by calculating the ratio between the number of cases with allelic losses and the number of informative cases (Table 2) .
Statistical Analysis
Data were presented as frequencies and/or percentages and compared by using the Mantel-Haenszel w 2 test for trend or the Fisher's exact test and the t test. Estimates for overall survival were calculated by the Kaplan-Meier method and compared using the log-rank test. All analyses were carried out using the SAS statistical software (SAS Institute, Inc., Cary, NC, USA). All P-values were based on twosided testing.
Results
Typical Carcinoids (Table 3) No allelic losses on X chromosome were found in any of the 126 informative microsatellite loci investigated in the nine typical carcinoids under examination.
Aypical Carcinoids (Table 3) Of the 17 atypical carcinoids studied, LOH on X chromosome for at least one microsatellite marker was found in nine, accounting for 61 out of 221 informative microsatellite loci (28%). Five tumors showed loss of most (#11, 15, 22) or all (#10, 23) informative markers. Four atypical carcinoids showed partial (#13b, 24) or interstitial (#17, 25) losses. Nine tumors showed retention of heterozygosity for all markers investigated. In two cases (#17 and 24), microsatellite instability was found with the marker DXS1047, as indicated by the appearance in the tumor tissue of a novel allele, not present in normal tissue. Tumor #13 was characterized by the presence of two histologically different areas, one with trabecular (#13a) and the other with solid structure (#13b). The trabecular area showed retention of heterozygosity with all the markers investigated, while the solid area showed LOH with the telomeric markers DXS1192 and DXS102 (Figure 2) . Primary tumor and a lymph node metastasis were investigated in case #26, and retention of heterozygosity for all informative markers was found in both.
Large Cell Neuroendocrine Carcinomas (Table 3) Of the six large cell neuroendocrine carcinomas examined, LOH on X chromosome was found in five, accounting for 53 out of 76 informative microsatellite loci (70%). In four cases, loss of most (#30, 32a) or all (#27, 28) of the informative markers investigated was found. One case (#31) showed partial losses concentrated in the long arm of X chromosome. One case (#29) showed retention of heterozygosity with all markers investigated. In the single case of poorly differentiated tumor with combined large cell and small cell carcinoma (#32), the large cell component (#32a) showed loss of all but two informative markers examined, while the small cell component (#32b) showed loss of all. Whenever LOH was found in both components, the same allele was affected. However, the extent of reduction of the allele height in the small cell component (#32b) was always much more pronounced than in the large cell component (#32a), often leading to the complete disappearance of allele ( Figure 3 ).
Small Cell Lung Carcinomas (Table 3)
Of the five pure small cell lung carcinomas investigated, LOH on X chromosome was found only in one out of 66 informative microsatellite loci (1.5%). Three tumors (#34, 35, 37) showed complete retention of heterozygosity, whereas one (#36) showed loss at a single microsatellite locus (DXS1192). The remaining tumor (#33) showed microsatellite instability at DXS990 locus.
Frequency of LOH in the Different Groups of Lung Neuroendocrine Tumors and Clinico-Pathological Correlations
The number of LOH events was significantly different in the four groups of lung neuroendocrine Figure 4 reveals a shorter survival rate in patients with LOH than in those without LOH, although a statistical significance was not reached. No association was found with age (P ¼ 0.83) or lymph node involvement (P ¼ 0.166). In large cell neuroendocrine carcinomas, no significant association was found between LOH status and any of the clinicopathologic parameters investigated.
Frequency of LOH: Comparison at Different
Microsatellite Loci (Table 2) When the tumor groups with significant occurrence of X chromosome LOH were considered (ie atypical carcinoids and large cell neuroendocrine carcinomas), four chromosomal regions more frequently deleted could be identified. LOH ratios above 40% were found at the following microsatellite markers: DXS996 (Xp22.3, 43%) -DXS207 (Xp22.2, 42%); MAOA (Xp11.4-Xp11.3, 42%); DXS56 (Xq13.2-Xq13.3, 41%); DXS1192 (Xq26, 47%) -DXS102 (Xq26, 50%).
Discussion
Lung neuroendocrine tumors comprise a heterogeneous group of tumor types characterized by different degrees of clinical aggressiveness. Thus, they represent a useful model for the study of genetic alterations associated with malignancy. In this regard, our study showed a progressive increase in the frequency of X chromosome LOH in lung neuroendocrine tumors, ranging from low-grade typical carcinoids to intermediate-grade atypical carcinoids to highly aggressive large cell neuroendocrine carcinomas. In contrast, small cell lung carcinomas presented only one exceptional loss. These results are in keeping with previous observations of a progressive accumulation of genetic defects from low-to high-grade neuroendocrine lung neoplasms. 8, 9 Although a transition of either typical or atypical carcinoids to high-grade neuroendocrine carcinomas is currently deemed to be unlikely, 10 we herein indicate that carcinoids and large cell neuroendocrine carcinomas may share common genetic alterations on X chromosome, suggesting a critical role for these chromosomal regions in the pathogenesis of both tumors. Moreover, the finding of several X chromosome LOH in large cell neuroendocrine carcinomas but not in small cell lung carcinomas supports the view that these highly aggressive lung neuroendocrine carcinomas are genetically different. [10] [11] [12] Among atypical carcinoids, the correlation between LOH status and clinicopathological parameters such as tumor size, pN and stage, as well as the separation between survival curves of patients with and without losses, showing a shorter survival time for the former, both suggest a correlation of X chromosome LOH with a more aggressive phenotype. Additional associations between LOH and other clinicopathological parameters may have been hidden by the relatively low number of cases investigated, in particular for large cell neuroendocrine carcinomas, due to the overall low frequency of these neoplasms coupled with their prevalence in male rather than in female patients. 13 The X chromosome has been implicated in many hereditary and sporadic diseases and LOH has been reported in different human tumors, especially in cancers of reproductive and urologic organs (breast, ovary, prostate, bladder; for a review see Liao et al 14 ) , with a few candidate oncosuppressor genes proposed. In the present study, the LOH status of X chromosome was assessed through a detailed allelotyping using 18 microsatellite markers distributed on both chromosomal arms, in an attempt to define minimal common deletion regions, that most likely harbor tumor suppressor genes. In this regard, although a statistical significance was not reached, it may be interesting to note that four chromosomal regions were found to include microsatellite markers with LOH rate above 40%: Xp22.3-22.2, Xp11.4-11.3, Xq13.2-13.3 and Xq26.
Xq26, investigated with the markers DSX1192 and DXS102 and appearing as the most frequently deleted region in the present study, was reported to show high frequency of LOH in several types of cancers, especially those of the ovary and breast. [14] [15] [16] [17] A potential oncosuppressor gene located in this region is the MEF (myeloid elf-1-like factor) gene, an ETS transcription factor located at Xq26.1. 18 In particular, MEF suppresses the tumorigenesis of human nonsmall cell lung carcinoma cell lines A549 both in vitro and in vivo, most likely through the inhibition of matrix metalloproteinases and interleukin-8 gene transcription. Also the glypican 3 (GPC3) gene, encoding for a membrane-bound heparan sulfate proteoglycan, maps at Xq26. 15 Mutations of GPC3 are implicated in the pathogenesis of the Simpson-Golabi-Behmel syndrome, an X-linked disorder characterized by overgrowth, dysplasia and multiple congenital anomalies. 15 GPC3 has been found to be silenced in breast and lung cancers, malignant mesotheliomas and ovarian cancer cell line.
14 Moreover, recent studies have shown that GPC3 expression is decreased in lung adenocarcinoma and in nonmalignant lung tissue of smokers. These data suggest that GPC3 may be a lung tumor suppressor gene involved in cigarette smoke-associated lung carcinogenesis. 19 In our study, Xq26 was the most frequently deleted region; however, a relationship between this LOH and cigarette smoke in atypical carcinoids and large cell neuroendocrine carcinomas seems to be unlikely because the same region was unaffected in small cell lung carcinoma, a lung cancer strongly associated with smoke. 20 Interestingly, in a single case of atypical carcinoid (#13), a relation of LOH restricted to the two markers at Xq26 with tumor histological arrangement was found, with the losses occurring only in the solid but not in the trabecular component of the tumor. This finding could explain on the one hand the reported genetic heterogeneity of atypical carcinoids as a function of tumor sampling, 21 and on the other, could support the transition of some atypical carcinoids directly from a pre-existing typical carcinoid. Analysis of further cases is warranted to substantiate this observation and to evaluate its biological significance.
LOH at Xp22.3-22.2, investigated in our study with the markers DXS996 and DXS207, was found in ovarian cancer, with allelic losses twice as frequent in patient carriers of germ-line BRCA1 mutations: these data suggest that a tumor suppressor gene important for BRCA1-associated carcinogenesis may be located at that region. 22 Moreover, LOH at pseudoautosomal regions at the end of Xp (Xp22.3) and Xq (Xq28) arms was found in sporadic breast cancers, in association with negative hormonal receptor phenotype, an indicator of poorer prognosis and more aggressive behavior in these neoplasms. 23 Microsatellite MAOA at Xp11.4-Xp11.3 is a dinucleotide repeat included in the monoamine oxidase A gene, which encodes for a mitochondrial outer membrane protein implicated in the catabolism of neuroactive and vasoactive amines in the central nervous system and in peripheral tissues. MAOA gene product preferentially catalyzes the oxidative deamination of biogenic amines such as 5-hydroxytryptamine, norepinephrine and epinephrine. 24 To our knowledge, no data on cancerassociated allelic losses involving the microsatellite MAOA, as well as DXS56 at Xq13.2-Xq13.3, have been reported in the literature so far.
In our study, a striking difference was found between the two types of high-grade neuroendocrine lung tumors, with the highest frequency of X chromosome losses observed in large cell neuroendocrine carcinomas and the virtual absence of such losses seen in small cell lung carcinomas. This result contributes to the current debate on the histogenetic relationship between these two neuroendocrine tumor types of the lung, with particular regard to their origin from either common or independent progenitor cells. Indeed, both genetic similarities 8, 9, [25] [26] [27] and striking genetic differences 11, 12 between large cell neuroendocrine carcinomas and small cell lung carcinomas have been reported. Both tumor types have been found to show a high number of chromosomal aberrations, sharing losses of chromosome 3p, 4, 5q, 13 and gains of 5p, all changes commonly observed also in nonneuroendocrine lung carcinomas. 11 In contrast, if only aberrations peculiar to neuroendocrine tumors are considered, some of them (6p gains) have been found to be specific for large cell neuroendocrine carcinomas and others (loss of 10 and 16q, gain of 3q) for small cell lung carcinomas. 11 Moreover, although frequent abnormalities in the tumor suppressor gene Rb pathway have been shown in both types of high-grade lung neuroendocrine tumors, gene inactivation was found to be achieved through different mechanisms, mostly represented by Rb protein loss in small cell lung carcinomas, and by p16 protein loss and cyclin D1 overexpression in large cell neuroendocrine carcinomas. 12 Our results on X chromosome LOH introduce further evidence for different genetic events between large cell neuroendocrine carcinomas and small cell lung carcinomas.
Although combined small cell carcinoma is a well-recognized morphological variant of this tumor, 1 our findings of common genetic losses in either large-or small cell component point to a different molecular pathogenesis of this tumor from the pure forms of small cell lung carcinomas. Further studies on a larger number of combined lesions are clearly warranted to elucidate this important point.
Taken together with previous data from other tumor types, our results allow us to assume that X chromosome LOH is a common and specific feature of malignant neuroendocrine tumors of foregutderivative organs. Indeed, the association between X chromosome allelic losses and malignancy has been clearly documented in endocrine tumors of the stomach 7 and pancreas. 6, 28 Moreover, X chromosome LOH has recently been found to correlate with aggressive post operative tumor X chromosome in lung endocrine tumors T D'Adda et al growth in pancreatic gastrinomas. 29 In contrast, endocrine tumors of midgut and hindgut origin, even if malignant, did not present a significant occurrence of X chromosome losses. 6 In this regard, it is worth noting that neuroendocrine tumors of foregut and midgut origin differ also in the genetic mechanisms involved in tumor induction. The inactivation of the MEN1 gene, in fact, appears to be restricted to neoplasms of foregut derivative organs, as shown by both LOH studies at 11q13 30, 31 and by the pattern of tumor involvement in the MEN1 syndrome. 32 In midgut tumors, in contrast, evidence for the involvement of SDHD (succinate-ubiquinone oxidoreductase subunit D) gene at 11q23 33 and/or of a still unidentified tumor suppressor gene located on chromosome 18q, potentially responsible for early tumor development, support different mechanisms of tumor induction. 34, 35 In conclusion, these results provide a genetic basis for the classification of Williams and Sandler 5 and support the assumption that at least two genetically distinct families of neoplasms (of foregut and midgut origin, respectively) may be identified among neuroendocrine tumors arising in the lung and gastroenteropancreatic tract.
